Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05605756 · ClinicalTrials.gov registry record · Phase 4
BOTOX Effects on Seizure Severity and Susceptibility
A Phase 4 study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT05605756 is a Phase 4 study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 3 participants.
The verdict
NCT05605756, a Phase 4 study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this research is to determine whether BOTOX injections will reduce seizure frequency and severity. We chose to test its effects on epilepsy because epilepsy and migraine have common features so, are often treated with common drugs.
Interventions
- DRUG OnabotulinumtoxinA 145 UNT [Botox]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2024-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05605756
The ClinicalTrials.gov registry entry for NCT05605756 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OnabotulinumtoxinA 145 UNT [Botox] is the first listed.
NCT05605756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05605756 about?
NCT05605756 is a clinical study titled "BOTOX Effects on Seizure Severity and Susceptibility". The purpose of this research is to determine whether BOTOX injections will reduce seizure frequency and severity. We chose to test its effects on epilepsy because epilepsy and migraine have common features so, are often treated with common drugs.
What is the current status of trial NCT05605756?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2023-03-01. Estimated completion is 2024-12-01.
What interventions are being tested in trial NCT05605756?
The interventions under investigation include: OnabotulinumtoxinA 145 UNT [Botox] (DRUG).
Who is sponsoring clinical trial NCT05605756?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.